Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

New psychoactive substances, originally developed as potential analgesics but abandoned due to adverse side effects, may ...

An experimental new medication claims to help people lose weight without muscle loss. Here’s what you need to know about the ...

Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Dec 11 () - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ​late-stage trial, outperforming its blockbuster drug Zepbound and ...